ArticleFrontiers in endocrinology2026
Syntaxin 4 protects islet β-cells from cytokine-induced senescence.
Article in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Introduction: Type 1 diabetes (T1D) is characterized by progressive loss of pancreatic b-cell function, which is accelerated by cytokine-induced senescence and the accompanying senescence-associated secretory phenotype (SASP). We investigated whether Syntaxin 4 (STX4), a t-SNARE protein previously recognized for its cytoprotective properties, can mitigate b-cell senescence under diabetogenic stress. Methods: Ectopic STX4 expression was induced in MIN6 cells, human islets, and murine islets, followed by cytokine and bleomycin treatment to model senescence-inducing stress and subsequent quantification of senescence markers (p21 and γH2AX). b-cell specific STX4 expression was induced in the non-obese diabetic (NOD) mice and senescence-markers, including p21, γH2AX, and nuclear Lamin B, were subsequently quantified. In parallel, we analyzed single-cell RNA sequencing and performed conditioned-medium proteomics to define STX4-dependent transcriptional and secretome changes, respectively. Results: STX4 overexpression markedly reduced cytokine-induced accumulation of p21 and γH2AX in MIN6 cells, human islets, and murine islets. In NOD mice, induced STX4 expression reduced p21 and γH2AX accumulation and preserved nuclear Lamin B1 in pancreatic b-cells, supporting an Discussion: These findings indicate that STX4 protects β-cells from cytokine or bleomycin-induced senescence and suggest that enhancing STX4 activity may be a therapeutic strategy to preserve functional β-cell mass in T1D.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.